The POD1UM-303/InterAACT2 trial demonstrated a 37% reduction in the risk of progression or death (PFS) for patients treated with retifanlimab and chemotherapy compared to chemotherapy alone. How significant is this improvement for patients with advanced SCAC, considering the lack of FDA-approved treatments for this condition?

The trial showed an approximately 6-month improvement in overall survival (OS) for patients treated with retifanlimab and chemotherapy, with a trend toward statistical significance. Could you elaborate on the potential impact of this OS extension for patients with inoperable SCAC?

The overall response rate (ORR) and duration of response (DOR) were both improved with the addition of retifanlimab. What does this mean for the quality of life and disease management in these patients?

Retifanlimab was generally well-tolerated, with a safety profile consistent with other checkpoint inhibitors. Given the chronic nature of SCAC and its recurrence, how important is the tolerability of this combination therapy for long-term patient care?

SCAC remains a rare and neglected disease with an increasing incidence, particularly among patients with HIV. How does the potential approval of retifanlimab address the current gaps in treatment for this high-risk population?

Considering that platinum-based chemotherapy has been the standard treatment for decades, how do these results position retifanlimab in potentially reshaping the treatment paradigm for metastatic or recurrent SCAC?

Patients with well-controlled HIV were included in the study. How might retifanlimab offer new hope for HIV-positive patients, who are disproportionately affected by SCAC, in terms of efficacy and safety?

Incyte plans to file a supplemental Biologics License Application (sBLA) for retifanlimab by the end of 2024. What are the critical steps Incyte must take to secure regulatory approval, and how might this drug influence the treatment landscape for SCAC globally?